Gb1211
WebMar 13, 2024 · GB1211 displayed favorable PK properties, with low to moderate variability of systemic exposure and minor food-effect on drug disposition. GB1211 is the first orally … WebOct 19, 2024 · Galecto has committed to supply GB1211 for the Phase 2 trial. Galectin-3 is overexpressed in many cancers, including melanoma and head and neck squamous cell …
Gb1211
Did you know?
WebGB1211 (Galecto Biotech) is an oral galectin-3 inhibitor under development for fibrotic disease. First described in 1971, galectin-3, a unique subtype of a 15-member family of … WebMay 26, 2024 · GB1211 is designed to counter these effects. GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and exhibited dose-dependent pharmacokinetics. About Galecto
WebDec 13, 2024 · GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy … Web1 day ago · GB1211 is a candidate in Galecto’s pipeline that is being evaluated in non-small cell lung cancer in a phase II GALLANT-1 trial and in melanoma head and neck squamous cell carcinoma in a phase ...
WebMar 2, 2024 · If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely. IP authentication when working within your organization’s network. Login with a username/password associated to your organization’s account. Persisted access using your organization’s identifier ... WebSep 9, 2024 · GB1211 displayed favorable PK properties, with low to moderate variability of systemic exposure and minor food-effect on drug disposition. GB1211 is the first orally bioavailable small molecule galectin-3 inhibitor and is a potential novel treatment for diseases associated with high galectin-3 levels. These findings support further clinical ...
Webblockade was reversed in the presence of Gal-3 and dramatically improved by GB1211. Similarly, in cell systems expressing high levels of PD-1 or PD-L1, Gal-3 reduced the binding of pembrolizumab and atezolizumab to their respective targets on cell surfaces that was also reversed by GB1211. Con-
WebSep 13, 2024 · GB1211 has the potential to treat multiple types of cancer and fibrotic diseases. Galecto’s initial target indications for GB1211 are NSCLC, a cancer indication … toyota factory listWebFeb 1, 2024 · Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary ... toyota factory madison alWebChronic liver injury results in immune-driven progressive fibrosis, with risk of cirrhosis development and impact on morbidity and mortality. Persistent liver cell damage and death causes immune cell activation and inflammation. Patients with advanced cirrhosis additionally experience pathological bacterial translocation, exposure to microbial … toyota factory liftWebFeb 28, 2024 · A Study to Compare Pharmacokinetics of GB1211 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT05747573 toyota factory locations in americaWebMay 26, 2024 · GB1211, Galecto’s orally active, potent and selective galectin-3 inhibitor candidate, is designed to block the galectin-3 carbohydrate recognition domain and reduce tumor resistance to PD-1/PD-L1... toyota factory lift kit 4runnerWebDec 13, 2024 · GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and had dose-dependent pharmacokinetics. About Galectin-3 in Liver Cirrhosis toyota factory maintenanceWebGB1211 is also being studied in pts with hepatic impairment (NCT05009680). Trial design GALLANT-1 is a 3-part phase 1b/2a study that will investigate safety and efficacy of GB1211 + atz vs placebo + atz in pts with advanced or metastatic NSCLC that expresses PD-L1 on ≥50% of tumour cells. toyota factory lift kit tacoma